Skip to content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Thursday, March 5, 2026
World Today News
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Copyright 2021 - All Right Reserved
Home » Obesidad
Tag:

Obesidad

Health

Spanish Experts Call for Empathetic Obesity Reporting & Language Update

by Dr. Michael Lee – Health Editor February 24, 2026
written by Dr. Michael Lee – Health Editor

Madrid – The Spanish Society of Endocrinology and Nutrition (SEEN) convened a training session on Tuesday for journalists, patient advocacy groups and health communicators to address how obesity is reported in the media. The initiative, titled “Words Matter: Improving the Approach to Obesity,” aimed to promote more accurate, empathetic, and scientifically grounded coverage of the chronic disease.

The session, held in Madrid and streamed online, was supported by the National Association of Health Information Specialists (ANIS), the Spanish Forum of Patients (FEP), and the National Association of People Living with Obesity (ANPO). Graziella Almendral, a science and health journalist, moderated the event, emphasizing the need to analyze not just the clinical aspects of obesity, but too the impact of media narratives on public perception and the lives of those affected.

Almendral referenced actor Brendan Fraser’s experience preparing for his role in “The Whale,” noting his emphasis on understanding the lived experience of a person with obesity. She argued that health journalism should adopt a similar approach, prioritizing comprehension and empathy before constructing a news narrative.

Dr. Javier Salvador, Professor Emeritus of Endocrinology at the University of Navarra and a member of SEEN’s Obesity Area, underscored the fundamental understanding of obesity as a “highly prevalent, chronic, and complex disease.” He stressed that obesity is not curable and requires ongoing management, impacting more than 200 different complications, debunking the notion that it is solely a matter of lifestyle or aesthetics.

Dr. Salvador also highlighted the growing prevalence of obesity in Spain, currently affecting 18-23% of the adult population, with projections indicating a potential rise to 37% by 2035. He called for structural responses based on scientific evidence to address this trend.

A central theme of the session was the issue of stigma. Dr. Salvador warned that despite the biological and physiological basis of obesity, a persistent belief remains that it is solely a matter of willpower. He termed this “falsehood” a source of profound and painful consequences, rooted in “weight bias” and the assumption of personal culpability. He advocated for person-centered language, suggesting framing individuals as “people living with obesity” rather than “obese people.”

Andoni Lorenzo Garmendia, President of the FEP, echoed these concerns, stating that obesity remains one of the most stigmatized diseases despite its complexity. He emphasized that stigma is not harmless, impacting health, quality of life, and access to healthcare. He noted that individuals often face guilt, social judgment, and inequality, leading to delayed medical consultation, treatment non-adherence, and potentially harmful self-treatment.

The discussion also addressed the social determinants of obesity, with experts noting a correlation between lower socioeconomic status and higher prevalence rates. Lorenzo Garmendia pointed out that individuals in lower socioeconomic brackets face greater exposure to obesogenic environments and barriers to accessing healthy food and healthcare.

SEEN announced plans to develop specific guidelines on respectful language and to update its adult obesity management guide, incorporating the work of its Inequality and Stigma Group. The society already provides recommendations to media outlets aimed at combating stigmatization.

Federico Luis Moya, President of ANPO, emphasized the need for coordinated efforts between patient organizations, scientific teams, and clinical practitioners to effectively address obesity, recognizing its complexity and multifaceted nature.

February 24, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Mounjaro Approved in Europe for Obesity & Heart Failure: New Hope for Patients

by Dr. Michael Lee – Health Editor February 17, 2026
written by Dr. Michael Lee – Health Editor

The European Medicines Agency (EMA) has approved the expanded employ of tirzepatide, marketed as Mounjaro, to include treatment for obesity and a specific type of heart failure, according to announcements made on February 16th and 17th, 2026.

The approval extends Mounjaro’s application beyond its existing authorization for type 2 diabetes, which is not satisfactorily controlled through diet and exercise. The EMA’s decision covers the treatment of obesity and heart failure with preserved ejection fraction (HFpEF) in adults. Clinical trial data demonstrated a 38% reduction in the risk of events related to heart failure, including hospitalizations or the need for intensified treatment, among patients treated with tirzepatide. The drug also led to a 56% reduction in hospitalization specifically for heart failure, alongside significant improvements in physical function and a 14% reduction in body weight over 52 weeks of therapy.

The trials, conducted across ten countries but not including Spain, involved 731 participants and utilized weekly injections of tirzepatide at doses of five, ten, and fifteen milligrams, alongside a placebo. The study was designed as a multicenter, randomized, double-blind, parallel-controlled trial to assess the impact of the drug on mortality, cardiovascular events, and physical limitations associated with heart failure, with a follow-up period of 104 weeks.

Mounjaro is an agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. While already approved by the Spanish Ministry of Health for type 2 diabetes, it is not currently covered by the national health insurance system, unlike semaglutide, the active ingredient in Ozempic, which also treats obesity and diabetes. In 2024, Spain’s public health system spent 403 million euros on prescriptions for semaglutide, with demand increasing by approximately 40% annually over the past three years.

Discussions are currently underway between pharmaceutical company Lilly and Spanish health authorities regarding potential public funding for Mounjaro, though no immediate commitment has been made. The EMA’s approval now expands the potential patient base for the drug to include individuals with obesity, even in the absence of other comorbidities, and those suffering from HFpEF.

February 17, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Alzheimer’s Research: Skepticism Towards New Therapies | Eva Carro

by Dr. Michael Lee – Health Editor February 15, 2026
written by Dr. Michael Lee – Health Editor

Alzheimer’s disease research is seeing a shift in focus from traditional kinase inhibitors towards the development of multi-target ligands, a strategy utilizing protein-templated synthesis, according to recent findings published by Wiley Online Library.

The evolving approach comes as the medical community cautiously observes the potential of new Alzheimer’s drugs to slow the disease’s progression. A recent report in EL PAÍS English highlighted a new drug showing promise in this area, though skepticism remains within the field.

Eva Carro, a specialist in neurodegenerative diseases including Alzheimer’s, has expressed reservations regarding these emerging therapies. The specifics of Carro’s concerns were not detailed in the available sources, but her stance underscores a broader debate about the efficacy and long-term effects of current and prospective Alzheimer’s treatments.

The protein-templated synthesis method, as detailed in the Wiley Online Library publication, aims to create ligands capable of interacting with multiple targets within the complex biological pathways associated with Alzheimer’s. This contrasts with the more focused approach of kinase inhibitors, which target specific enzymes. Researchers believe that a multi-target approach may be more effective in addressing the multifaceted nature of the disease.

The development of these multi-target ligands represents a significant investment in research and development, with the hope of providing more effective therapeutic options for the millions affected by Alzheimer’s disease globally. Further research is ongoing to assess the safety and efficacy of these compounds.

February 15, 2026 0 comments
0 FacebookTwitterPinterestEmail

Search:

Recent Posts

  • Song Ping, Former Top Chinese Leader, Dies at 109

    March 4, 2026
  • WV High School Wrestling: State Tournament Preview – Cameron, Oak Glen & More

    March 4, 2026
  • Regional & National Football League Selection | France Football Matches

    March 4, 2026
  • Gnocchi Parisienne: Recipe & Wine Pairing for Airy Cheese Dumplings

    March 4, 2026
  • Matsuoka’s Instagram Live Stream Interrupted by Alarm | Gaming Incident

    March 4, 2026

Follow Me

Follow Me
  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com


Back To Top
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com